

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	10/595,932
		FILING DATE	May 19, 2006
		APPLICANT	Mercep et al.
		GROUP	
		EXAMINER	
		ATTORNEY DOCKET NO.	PLP527USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	6,288,058	Sept. 11, 2001	Gil-Lopetegui et al.			
	2	6,897,211	May 24, 2005	Mercep et al			
	3	7,262,309	Aug. 28, 2007	Mercep et al			
	4	7,312,203	Dec. 25, 2007	Mercep et al			

Continue on page _____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

5	De Clerq, E. "Antiviral Drugs in Current Clinical Use." Journal of Clinical Virology, 2004, Vol. 30, pgs. 115-133.
6	Shih, Shin-Ru, et al. "Selective Human Enterovirus and Rhinovirus Inhibitors: An Overview of Capsid-Binding and Protease-Inhibiting Molecules." Medicinal Research Reviews, 2004, Vol. 24, No. 4, pgs. 449-474.
7	Sun Exposure and Skin Cancer (online), (retrieved on 2008-09-08). Retrieved from the internet, URL; http://www.medicinenet.com/script/main/art.asp?li=USA&articlekey=43077&page=1 .
8	Sun Exposure and Skin Cancer (online), (retrieved on 2008-09-08). Retrieved from the internet, URL; http://www.medicinenet.com/script/main/art.asp?li=USA&articlekey=43077&page=2 .
9	Viruses and Disease, Viral infections (online), (retrieved on 2006-09-08), retrieved from the internet, URL; http://en.wikipedia.org/wiki/Viral_infections .
10	Bhatt J.M., et al. "Current Clinical Trials in Amyotrophic Lateral Sclerosis." Expert Opinion in Investigational Drugs, 2007, 16(8), pgs 1197-1207
11	Nitu AN, et al. "Emerging Trends in the Pharmacotherapy of Chronic Pain." Expert Opinion in Investigational Drugs, 2003, 12(4), pgs. 545-559.
12	Serretti, A., et al. "The 5 HT2c Receptor as a Target for Mood Disorders." Expert Opinion in Therapeutic Targets, 2004, 8(1), pgs. 15-23.
13	Wood, M.D. et al. "Therapeutic Potential of Serotonin Antagonists in Depressive Disorders." Expert Opinion in Investigational Drugs, 2002, 11(4), 457,467.
14	"Biogenic Amines", http://www.nlm.nih.gov/egi/mesh/2008/MB_cgi?mode=&term=Biogenic+Amines&field=entry , accessed December 6, 2008.
15	"Neurotransmitter Agents", http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi , accessed December 6, 2008.
16	"Biogenic Polyamines", http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&term=Biogenic+Amines&field=entry , accessed December 6, 2008.
17	"Biogenic Monoamines", http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&term=Biogenic+Amines&field=entry , accessed December 6, 2008.

Continue on page _____

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	